Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-DKK1 monoclonal antibody JS015

A humanized monoclonal antibody directed against Dickkopf-related protein 1 (Dickkopf-1; DKK1), with potential immunomodulating and antineoplastic activities. Upon administration, anti-DKK1 monoclonal antibody JS015 binds to DKK1 and blocks the interaction between DKK1 and its ligands low-density lipoprotein receptor-related proteins (LRP) 5 and 6. This restores signaling through the Wnt/beta-catenin-dependent (canonical) pathway, and may decrease DKK1-mediated immunosuppressive effects in the tumor microenvironment (TME) and enhance anti-tumor immune responses. DKK1, an inhibitor of the Wnt/beta-catenin-dependent (canonical) signaling pathway, is overexpressed by and dysregulated in some cancers, as well as other diseases including osteoporosis, Alzheimer's disease and diabetes. 
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Code name:JS 015
JS-015
JS015
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search